STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer

Li, Xin; Jiang, Wenkai; Dong, Shi; Li, Wancheng; Zhu, Weixiong; Zhou, Wence

doi:10.3390/biom12101450

Open AccessReview

STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer

by

Xin Li

^1,†,

Wenkai Jiang

^1,†,

Shi Dong

¹,

Wancheng Li

¹,

Weixiong Zhu

¹ and

Wence Zhou

^1,2,*

¹

The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China

²

Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou 730030, China

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Biomolecules 2022, 12(10), 1450; https://doi.org/10.3390/biom12101450

Submission received: 11 August 2022 / Revised: 10 September 2022 / Accepted: 30 September 2022 / Published: 9 October 2022

(This article belongs to the Collection Recent Advances in Pancreatic Cancer)

Download

Browse Figures

Review Reports Versions Notes

Abstract

The signal transducer and activator of transcription (STAT) is a family of intracellular cytoplasmic transcription factors involved in many biological functions in mammalian signal transduction. Among them, STAT3 is involved in cell proliferation, differentiation, apoptosis, and inflammatory responses. Despite the advances in the treatment of pancreatic cancer in the past decade, the prognosis for patients with pancreatic cancer remains poor. STAT3 has been shown to play a pro-cancer role in a variety of cancers, and inhibitors of STAT3 are used in pre-clinical and clinical studies. We reviewed the relationship between STAT3 and pancreatic cancer and the latest results on the use of STAT3 inhibitors in pancreatic cancer, with the aim of providing insights and ideas around STAT3 inhibitors for a new generation of chemotherapeutic modalities for pancreatic cancer.

Keywords: STAT3; pancreatic cancer; drug therapy; molecular targeted therapy

Share and Cite

MDPI and ACS Style

Li, X.; Jiang, W.; Dong, S.; Li, W.; Zhu, W.; Zhou, W. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 2022, 12, 1450. https://doi.org/10.3390/biom12101450

AMA Style

Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules. 2022; 12(10):1450. https://doi.org/10.3390/biom12101450

Chicago/Turabian Style

Li, Xin, Wenkai Jiang, Shi Dong, Wancheng Li, Weixiong Zhu, and Wence Zhou. 2022. "STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer" Biomolecules 12, no. 10: 1450. https://doi.org/10.3390/biom12101450

APA Style

Li, X., Jiang, W., Dong, S., Li, W., Zhu, W., & Zhou, W. (2022). STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules, 12(10), 1450. https://doi.org/10.3390/biom12101450

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI